Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib

• Published in: Leukemia & lymphoma Vol. 56; no. 5; pp. 1385 - 1391
• Main Authors: Ohm, Lotta, Lundqvist, Adam, Dickman, Paul, Höglund, Martin, Persson, Ulf, Stenke, Leif, Carlsson, Katarina Steen, Björkholm, Magnus
• Format: Journal Article
• Language: English
• Published: United States Informa Healthcare 01.05.2015; Taylor & Francis
• Subjects: Adult; Aged; Antineoplastic Agents - economics; Antineoplastic Agents - therapeutic use; Chronic myeloid leukemia; Cost-Benefit Analysis; costs; Drug Costs; Female; Health Care Service and Management, Health Policy and Services and Health Economy; Health Sciences; Humans; Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi; Hälsovetenskap; imatinib; Imatinib Mesylate - economics; Imatinib Mesylate - therapeutic use; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - diagnosis; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - epidemiology; lifetime simulation; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Middle Aged; population-based; Prevalence; Protein Kinase Inhibitors - economics; Protein Kinase Inhibitors - therapeutic use; Quality-Adjusted Life Years; survival; Survival Analysis; costs; imatinib; lifetime simulation; Chronic myeloid leukemia; population-based; survival
• ISSN: 1042-8194; 1029-2403; 1029-2403
• DOI: 10.3109/10428194.2014.953141

Abstract Imatinib has revolutionized the treatment of chronic myeloid leukemia (CML). We evaluated clinical outcome and cost-effectiveness, using Swedish registry data based on patients with CML diagnosed 1973-2008. Outcome from three time periods (I: 1973-1979; II: 1991-1997; III: 2002-2008) associated with symptomatic treatment, interferon-α/stem cell transplant and implementation of imatinib, respectively, were compared and a lifetime cost-effectiveness model developed. Survival data from population registries, estimated resource use from clinical practice and quality of life estimates were employed. Substantial health gains were noted over time, paralleled by increased treatment costs. Median survival was 1.9, 4.0 and 13 years during the respective time periods. The incremental cost-effectiveness ratio (ICER) between periods III and II was €52 700 per quality-adjusted life year (QALY) gained. An estimated 80% price reduction of imatinib, related to patent expiry, would reduce this ICER to €22 700. Our data from four decades reveal dramatically improved survival in CML, paralleled by ICER levels generally accepted by health authorities.